Caplacizumab
Aus coViki
(Unterschied zwischen Versionen)
K |
K |
||
| Zeile 1: | Zeile 1: | ||
| + | {{up|PHA Biologicals}} | ||
| + | |||
Caplacizumab is a therapeutic monoclonal antibody which interferes with binding of platelets to extralong vWF multimers. It is first-line acute treatment option of TTP thrombotic thrombocytopenic purpura. I heard a talk at dgfn2020 and decided to aks the open question, might it be useful for covid19. 3 min answer :)))) | Caplacizumab is a therapeutic monoclonal antibody which interferes with binding of platelets to extralong vWF multimers. It is first-line acute treatment option of TTP thrombotic thrombocytopenic purpura. I heard a talk at dgfn2020 and decided to aks the open question, might it be useful for covid19. 3 min answer :)))) | ||
Aktuelle Version vom 18. Januar 2021, 20:49 Uhr
| PHA Biologicals |
Caplacizumab is a therapeutic monoclonal antibody which interferes with binding of platelets to extralong vWF multimers. It is first-line acute treatment option of TTP thrombotic thrombocytopenic purpura. I heard a talk at dgfn2020 and decided to aks the open question, might it be useful for covid19. 3 min answer :))))
Nothing at pubmed, some at pmc by full-text cooccurence of phrases, e.g.
| 32454092 2020. Microvascular thrombosis: experimental and clinical implications |
